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Animal model systems represent an important adjunct and surrogate for studies of osteoarthritis (OA) in
humans. They provide a means to study OA pathophysiology as well as aid in the development of
therapeutic agents and biological markers for diagnosing and prognosing the disease. Thus, it is of great
importance for the OA scientiﬁc community, both in academic as well as industrial research, to stan-
dardize scoring systems for evaluating the OA disease process and to make results between different
studies comparable. The task of the histopathology initiative of OARSI was to achieve a consensus of
scoring systems for the most important species used in OA animal model research (dog, guinea pig,
horse, mouse, rabbit, rat, and sheep/goat), which are presented in the various chapters in this special
volume of Osteoarthritis & Cartilage together with extra chapters on basic methodology (histochemistry,
statistics, morphometry), the speciﬁc terminology and a general discussion of animal models in OA
research. Standardized deﬁnitions are suggested for basic but essential terms such as “grading” and
“staging” in order to promote their consistent use and thereby promote improved understanding and
data interpretation across all model systems. Thus, this introductory chapter presents an overview of the
guiding principles for assessment of important OA animal model systems. Use of such systems, inde-
pendently or in conjunction with other systems in parallel, should facilitate comparability of results
across animal model studies.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Animal model systems represent an important adjunct and
surrogate for studies of osteoarthritis (OA) in humans. They provide
a means to study OA pathophysiology as well as aid in the devel-
opment of therapeutic agents and biological markers for diag-
nosing and prognosing the disease. In addition, joint degeneration
can be a major health issue in some animals including pets and
particularly for some species involved in occupational and sport
activities, such as horses and greyhounds. The grading and stagingto: Thomas Aigner, Medical
orferstr. 33, 96450 Coburg,
.
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s Research Society International. Pof osteoarthritic joint degeneration in animals are therefore rele-
vant to veterinarians as well as scientists trying to better under-
stand and treat the human disease.
Human OA is a heterogeneous condition leading to the same
ﬁnal clinico-pathologic results: pain and reduced joint function due
to a structurally damaged joint. Not surprisingly, for such
a heterogeneous disorder, identiﬁcation of an optimal model
system for the human disease is difﬁcult or impossible. Due to this
and other factors, such as cost, feasibility, and varying degrees of
similarity to features of OA in humans, multiple models employing
various species are currently used. These include spontaneous as
well as models induced by surgery, enzymes/chemicals, altered
mechanics or genetics (for review see the respective species
chapters as well as Poole et al. in this volume1). Unfortunately, all
these models differ in etiopathology and severity and no ‘gold-
standard’ has been identiﬁed so far that can encompass all aspects
of OA. Different subsets of human patients have disease etiologies
that vary, for instance genetic vs traumatic, and in this regard, canublished by Elsevier Ltd. All rights reserved.
Table I
Listing maturation age and maximal non-calciﬁed cartilage thickness as well as chondrocyte volume density (distal femoral cartilage) for the species described in this volume
and humans
Maturation age Thickness of distal femoral or tibial cartilage
(animal age)*
Chondrocyte volume density*
Human 15-20years 2.2 mm6 2%
Rabbit 8 m 0.2e0.4 mm (femur)7 2e12%
Rat 7e8 weeksy 0.17 mm (femur)8 10e25%
Sheep >2 years Femur: 0.6e1 mm
Tibia: 0.5e1.5 mm
(2e3-year old
castrated male)9,10
5e10% (2e4-year-old
castrated male)
Dog 10e18 months depending on breed 0.6e1.3 mm 2e12%
Goat >2 years 0.6e1.7 mm11 6e7%12
Horse 2 years 2 mm6 1.5e6%
Mouse 7e8 weeksy 0.030 mm (femur)8 15e40%
Guinea pig 7 months (femur) and 12e18 months
(tibia) of age13
0.3 mm at 6 months of age (tibia)14 15%
* Given are values for adult animals, which vary according the joint (regions), cartilage layer and age of the animal.
y Maturation age in rodents (rats and mice) refers to sexual maturity since the growth plates in adults remain open.
Table III
Grading of OA according to Pritzker et al. 20065
Grade Histological properties
0 Matrix: surface intact (normal architecture)
Cells: intact, appropriate orientation
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of the OA disease process, identiﬁcation of an appropriate disease-
mechanism oriented model may be a more realistic goal and better
suited to a particular investigation than the ‘gold standard/
universal model’, which has not been identiﬁed so far and might
not exist at all. Rather, as a consequence of this disease heteroge-
neity in the human, a plethora of models is required.
Factors inﬂuencing choice of the appropriate animal model
system include speciﬁc disease features such as skeletal maturation
(Table I), as well as their similarity to human joint physiology and
pathology. However, the choice is also tailored to the scientiﬁc
questions being asked and invariably economic considerations. For
instance, if one is interested in a therapeutic intervention that
blocks cell proliferation during the disease process, a model
showing signiﬁcant proliferative activity has to be employed in
order to test potential drug candidates. Altogether, the choice of the
right species and availablemodel is still an unresolved question and
largely depends on the interest of the study (for an in depth
introduction of the OA animal models available see the chapter by
Poole and colleagues in this volume1).
The Osteoarthritis Research Society International (OARSI)
histopathology initiative e the tasks and limitations
It is of great importance for the OA scientiﬁc community, both in
academic as well as industrial research, to standardize scoringTable II
Grading of OA according to Mankin et al. 19714
Feature Score Histological feature
Cartilage structure 0 Normal
1 Superﬁcial ﬁbrillation
2 Pannus and superﬁcial ﬁbrillation
3 Fissures to the middle zone
4 Fissures to the deep zone
5 Fissures to the calciﬁed zone
Chondrocytes 0 Normal
1 Diffuse hypercellularity
2 Cell clusters
3 Hypocellularity
Safranin-O staining 0 Normal
1 Slight reduction
2 Moderate reduction
3 Severe reduction
4 No staining
5 Total disorganisation
Tidemark 0 Intact
1 Tidemark penetrated by vesselssystems for evaluating the OA disease process and to make results
between different studies comparable. Therefore, about a decade
ago, OARSI started its ﬁrst histopathology initiative lead by Kenneth
Pritzker at the University of Toronto, Canada. At that time, two
assessment systems were predominantly used: the macroscopic
staging system devised by Collins2,3 and the histologic histo-
chemical grading system (HHGS) developed in 1971 byMankin and
colleagues4 (Table II). The OARSI initiative led to the development of
the Pritzker-score published in 20065 (Table III). The task of the
follow-up histopathology initiative was to achieve a consensus of
scoring systems for the most important species used in OA animal
model research. It was explicitly not the task of this initiative to
characterize or qualify animal models for utilization. Such an
attempt was made by CAN (Canadian Arthritis Research Network)
in collaboration with OARSI in 2006: a summary of the results of
this work is included in this volume (Poole et al. 20081). Thus, the
core task of this histopathology initiative was to propose species-
speciﬁc consensus scoring systems which would be reasonably
easy to use and which could be readily adopted by the community.1 Matrix: superﬁcial zone intact, oedema and/or superﬁcial
ﬁbrillation (abrasion), focal superﬁcial matrix condensation
Cells: cell death, proliferation (cluster formation), hypertrophy
2 As above:
Matrix: discontinuity at superﬁcial zone (deep ﬁbrillation).
 Loss of PG-staining in upper 1/3 of cartilage.
 Focal perichondral increased PG-stain in middle zone.
 Disorientation of chondron columns
3 As above:
Matrix: vertical ﬁssures into middle zone and branched ﬁssures
 Loss of PG-staining into lower 2/3 of cartilage
 New collagen formation
Cells: cell death, regeneration, hypertrophy in cartilage domains
adjacent to ﬁssures
4 As above:
Cartilage matrix loss with delamination of superﬁcial zone
excavation with matrix loss from superﬁcial to middle zone
Formation of cysts in the middle layer
5 Complete matrix loss with denudation of the sclerotic
subchondral bone or ﬁbrocartilage
 Microfracture with repair limited to bone surface.
6 Bone remodelling (more than osteophyte formation only)
with microfracture, ﬁbrocartilage and osseous repair above
the previous surface
Table IV
Deﬁning important terms related to the evaluation of joint pathology
Term Explanation
Assessing/
evaluating
General activity of analyzing something
Scoring A general term denoting an evaluation or
assessment performed in a (semi)quantitative or
qualitative manner
Measuring Assessing/evaluating something in a quantitative manner
Grading Scoring microscopically or macroscopically at
a speciﬁc site or region
Staging Scoring the overall disease status
(mostly done macroscopically, but can also be done
microscopically, e.g., histologically whereby grades
are multiplied by extent of lesions; could also be
performed radiographically or clinically)
Extent/extension Geographic area or scope of tissue involvement
(i.e., cartilage, bone, joint capsule etc.)
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systems in parallel, could facilitate comparability of results across
animal model studies.
At this stage, the suggested scoring criteria cannot be considered
perfect or ﬁnal: instead, we encourage the community to use them
and provide feedback to inform a revision of the criteria within 5
years. Thus, this work is seen as a starting point and not a ﬁnal
consensus. We envision the need for further validation and invite
your suggestions.
The process taken e general criteria applied
Initially, the most relevant species (i.e., dog, guinea pig, horse,
mouse, rabbit, rat, and sheep/goat) as well as experts working in
this area were identiﬁed. The team discussed the major topics and
approach, then divided into sub-teams coordinated by different
experts in the respective species (corresponding to the ﬁrst and
corresponding authors of the respective chapters in this volume).
At the outset, an extensive literature review was performed for all
species linking “OA AND [species] AND model” which revealed in
some instances, more than a 100 papers (e.g., guinea pig) while in
other species, less than 20 (e.g., horse). In particular, few papers
dealt speciﬁcally with new scoring systems, but rather dealt with
modiﬁed versions of previously published systems (primarily the
Mankin scoring system). These papers were not considered to be
speciﬁcally relevant for the present work except as documentation
of the usage of this respective system. Thus, the proposed scoring
systems are not primarily a review of existing work, but a sugges-
tion based on a combination of the literature and experience of core
experts in the ﬁeld. The product is a consensus-based scoring
system for each species, which is intended to make studies of
a particular species more comparable in the future.
Clearly, there will never be a perfect scoring system fulﬁlling all
needs in all respects: but the basic requirement5 is simplicity such
that the scoring criteria should be easy to follow and reproducible
for single observers as well as multiple observers. In order to ach-
ieve this, we have chosen to deﬁne/describe criteriawithin tables as
well as to show them speciﬁcally within a corresponding ﬁgure,
thus combining a written and a visual score. This should allow both
experienced as well as less experienced investigators to apply the
criteria reliably. Obviously, the scoring systems should be useful
(“utility”) for assessing changes and they should permit semi-
quantitative scoring of sufﬁcient accuracy to reﬂect the changes
happening within the joint (“scalability”). We have also chosen to
assess the inter-rater reliability of the recommended scoring
systems comparing, in most cases, the reliability of experienced
and inexperienced graders (see respective chapters).
In summary, we tried to keep the core categories simple, easy to
execute, and as reproducible as possible. One important decision to
be made is obviously which tissues should be included in the
assessment of joint degeneration. Most studies concentrate on
changes occurring in articular cartilage (sometimes including
osteophyte formation); only very few include changes in the
synovial membrane and the subchondral bone. Periarticular tissues
are hardly examined at all, though menisci, ligaments, tendons and
muscles obviously play some role in the disease process. In this
volume, we summarize what is known of the scoring of these
important other joint tissues in anticipation of a more compre-
hensive analysis to evolve over the next 5 years.
Scoring: grading and staging
For any scoring, standard sampling within one study and
between studies is crucial for comparability of results, and analo-
gous to the necessity and utility of standard embedding andstaining procedures. However, when modiﬁcations are needed,
depending on the study, careful consideration must be given to the
types of modiﬁcations to maximise comparability. Evaluators
should be blinded to the animal status in the study. In addition,
appropriate statistical methodology has to be applied (for review of
suitable methods see Pearce et al. in this volume).
In general, the process of joint destruction can be categorized by
pathogenesis (“typing”), or quantiﬁed according to its extent
(“staging”), and level of focal damage (“grading”). Typing of lesions
in animal models is less relevant compared to the human disease,
as most of these animal systems are narrowly deﬁned (consisting
most often of externally induced joint damage). “Grading” and
“staging” are quite relevant to human and animal joint degenera-
tion, but the nomenclature itself has been under debate and
deserves clariﬁcation also for the sake of this atlas (see Table IV). By
analogy to “grading” and “staging” in tumor pathology, we suggest
using “grading” for the evaluation/assessment of histological
changes of a tissue (cartilage, synovial membrane, subchondral
bone, etc.) at one or more sites of joint destruction. “Staging”
should refer to the assessment of the overall disease process
independent of the method used. Thus staging could be performed
clinically, radiographically, macroscopically or histologically.
Grading and staging both represent an attempt at “scoring”, a term
which we suggest be used to describe an evaluation or assessment
performed in a (semi)quantitative or qualitative manner.
Grading refers to the evaluation or assessment of a local region
or site within a joint area. Results of grading might correlate
signiﬁcantly with results of staging if (1) the specimen is taken from
the worst area of joint destruction, and (2) the graded lesion
represents more than a very focal lesion. Staging endeavors to
integrate the heterogeneity of processes and lesions representative
of the disease (in our case OA) into a global score. Usually, staging is
done by macroscopic scoring of changes observed in the affected
tissues (i.e., cartilage, bone, joint capsule, etc.). A staging system,
which evaluates the disease grade multifocally and extensively and
“multiplies” the local grades by the affected area (¼“extent”) is
likely to increase the accuracy of staging (as e.g., the Pritzker
scoring system5), but leads to a much more complex scoring
procedure that is often too complicated for routine use. Further-
more, a staging system may not be relevant if one is interested in
the biology of a speciﬁc tissue area; in this situation, the (local)
grade of the tissue pathology is more appropriate. So the option
adopted here is to use grading and staging for all samples in
parallel: e.g., “low grade e high stage” can be interpreted as a “less
damaged cartilage region in a joint with extensive and advanced
disease”. Similarly, “moderate grade e low stage” would indicate
a signiﬁcantly damaged cartilage region in an overall rather well
T. Aigner et al. / Osteoarthritis and Cartilage 18 (2010) S2eS6 S5preserved joint. This approach provides important information
about both aspects of joint degeneration namely the local situation
and the overall scope or status of the disease.
One limitation of all scoring systems is that the relative impor-
tance of the different cartilage pathology parameters scored is not
taken into account. This reﬂects the fact that our understanding of
which changes are the most important in the pathophysiology,
progression or treatment of OA is lacking. Another important issue
confronting histological analysis is the variability of damage within
a single section e.g., across one tibial or femoral condyle, the
severity of cartilage damage can vary and the percentage area
affected by the different degrees of damage is not adequately
measured with either the Mankin-based systems or the Pritzker-
score (for amore sophisticated scoring approach accounting for this
see the rabbit section in this volume).
As changes in the cartilage, particularly in surgically induced OA
models, are often very focal, all histopathological analyses are
plagued by issues and questions of sampling e i.e., the number of
joint regions and sections within each region that should be eval-
uated. Animal models, at least those including smaller species, have
the advantage of considerably smaller joints compared to the
human (and e.g., the horse) allowing total sampling and reduction
of sampling artefacts. Whether sections for histological comparison
in a therapeutic trial should be cut from the same anatomical
location or through the most severe lesion in the joint regardless of
location is problematic. The former allows for the best comparison
given the pre-existing topographical differences in morphology,
biochemistry and gene expression that exist in normal joints.
However, if a therapy under investigation resulted in the maximal
cartilage lesion being in a different anatomical location (such as
may occur if joint mechanics were affected by the treatment), then
false positive or negative results may arise from comparing the
same topographical region. In the latter scenario, additional
sections should therefore be cut to enable comparison of histopa-
thology from the sites of the maximal lesion and sites representing
the same topographic regions of the compared joints. The number
of joint regions to be evaluated histologically may be driven by the
additional analyses that are to be simultaneously undertaken such
as cartilage biomechanics, biochemistry, gene expression, etc.
Where to go from here
There is a need to validate and improve the currently available
scoring systems. This includes experimental studies to explicitly
evaluate the longitudinal course of the disease process in all the
animal models employed to more clearly deﬁne the time course
of events which is not feasible in humans. Ultimately, evaluation
of OA needs to encompass an evaluation of the whole joint organ
given the importance of the non-cartilaginous structures for the
disease process. This includes synovial changes and subchondral
bone changes, as well as alterations of the menisci in the knee,
the tendons and ligaments and other periarticular tissues. Finally,
the success of animal models and their related scoring systems
depends on their relevance to the human, both for studying the
human disease process as well as for testing disease modifying
agents or biological markers. The success of animal models is
somewhat hampered, as indicated above, by our limited knowl-
edge of the human disease. Attempts to understand disease in
humans and animal models are both needed and can support and
inform each other. As we come to better understand the human
disease, we will better reﬁne the use of animal models employed,
and conversely, the knowledge gained by studying the animal
models will shed light on the human disease. This applies not
only to pathogenesis, but also to scoring systems of the disease
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